Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
In this study we examined the influence of different lipid lowering drugs (xantinolnicotinate (Xn), bezafibrate (Bf) and a combination of inositolnicotinate and clofibrate (In-Cl)) on the lipid and lipoprotein concentration in 61 hyperlipidemics of the types IIb, IV and V. Treatment with the 3 drugs showed a significant LDL-cholesterol decrease in type IIb and a LDL-cholesterol increase in the types IV and V. Concerning protective HDL lipoproteins an increase of HDL-cholesterol could be observed in all three types only by treatment with xantinolnicotinate and bezafibrate. Concomitantly in type V a type conversion to type IV could be observed under drug treatment regarding the chemical composition of the lipoprotein fractions VLDL, LDL and HDL.
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001629:Bezafibrate; D002784:Cholesterol / Q000097:blood*; D002994:Clofibrate / Q000627:therapeutic use; D002995:Clofibric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000097:blood / Q000188:drug therapy*; D006954:Hyperlipoproteinemia Type V / Q000097:blood / Q000188:drug therapy*; D007294:Inositol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008074:Lipoproteins / Q000097:blood*; D009539:Nicotinic Acids / Q000627:therapeutic use*; D014971:Xanthinol Niacinate / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D008074:Lipoproteins; D009539:Nicotinic Acids; D007294:Inositol; D002995:Clofibric Acid; D014971:Xanthinol Niacinate; D002784:Cholesterol; C005193:Inositol Niacinate; D002994:Clofibrate; D001629:Bezafibrate